Company logo

CVAC - CureVac N.V.

NASDAQ -> Healthcare -> Biotechnology
Tübingen, Germany
Type: Equity

CVAC price evolution
CVAC
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Current assets
Cash $464.14 $537.92 $617.52 $495.8
Short term investments $3.46 $5.35 $3.07 $4.49
Net receivables $10.47 $6.44 $3.38 $6.29
Inventory $23.3 $22.19 $24.68 $23.99
Total current assets $536.83 $603.21 $686.92 $584.03
Long term investments
Property, plant & equipment $272.22 $261.57 $253.16 $241.7
Goodwill & intangible assets $30.47 $31.7 $30.6 $31.78
Total noncurrent assets $305.73 $296.27 $286.76 $276.44
Total investments $3.46 $5.35 $3.07 $4.49
Total assets $842.57 $899.48 $973.67 $860.47
Current liabilities
Accounts payable $12.57 $13.42 $14.97 $73.46
Deferred revenue $92.57 $98.76 $103.16 $107.31
Short long term debt $5.53 $5.21 $5.06 $4.98
Total current liabilities $150.68 $156.28 $90.3 $156.22
Long term debt $36.58 $35.28 $36.09 $37.11
Total noncurrent liabilities $89.62 $94.16 $169.97 $170.99
Total debt $42.11 $40.48 $41.15 $42.09
Total liabilities $240.3 $250.43 $260.27 $327.22
Shareholders' equity
Retained earnings -$1479.33 -$1430.65 -$1363.23 -$1305.81
Other shareholder equity -$0.15 -$0.12 -$0.12 -$0.14
Total shareholder equity $602.26 $649.05 $713.4 $533.25
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $495.8 $811.46 $1322.59 $30.68
Short term investments $4.49 $4.65 $2.62 $1.46
Net receivables $6.29 $18.5 $1.01 $15.69
Inventory $23.99 $56.16 $14.53 $6.2
Total current assets $584.03 $940.02 $1389.85 $57.17
Long term investments
Property, plant & equipment $241.7 $200.39 $100.59 $61.69
Goodwill & intangible assets $31.78 $13.24 $14.15 $5.7
Total noncurrent assets $276.44 $218.22 $121.5 $73.44
Total investments $4.49 $4.65 $2.62 $1.46
Total assets $860.47 $1158.24 $1511.36 $130.62
Current liabilities
Accounts payable $73.46 $127.7 $21.68 $6.47
Deferred revenue $107.31 $142.09 $658.05 $73.52
Short long term debt $4.98 $3.47 $3.23 $2
Total current liabilities $156.22 $357.73 $247.62 $28.09
Long term debt $37.11 $25.42 $52.04 $77.14
Total noncurrent liabilities $170.99 $112.03 $552.39 $145.34
Total debt $42.09 $28.89 $55.28 $79.15
Total liabilities $327.22 $469.77 $800.01 $173.42
Shareholders' equity
Retained earnings -$1305.81 -$1056.79 -$645.07 -$515.95
Other shareholder equity -$0.14 -$0.03 $0.06 $0.02
Total shareholder equity $533.25 $688.48 $711.35 -$42.8
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue $16.48 $7.58 $7.13 $11.69
Cost of revenue $24.28 $25.85 $20.63 $80
Gross Profit -$7.8 -$18.27 -$13.51 -$68.31
Operating activities
Research & development $27.25 $30.87 $24.25 $27.62
Selling, general & administrative $19.51 $23.65 $24.11 $27.15
Total operating expenses $46.24 $53.53 $46.85 $53.2
Operating income -$54.03 -$71.8 -$60.35 -$121.51
Income from continuing operations
EBIT -$44.59 -$65.61 -$56.47 -$128.12
Income tax expense $0.01 $0.03 $0 $0.03
Interest expense $4.08 $1.78 $0.95 $0.63
Net income
Net income -$48.68 -$67.41 -$57.42 -$128.78
Income (for common shares) -$48.68 -$67.41 -$57.42 -$128.78
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $67.42 $102.99 $48.87 $17.42
Cost of revenue $183.99 $238.19 $14.17 $27.98
Gross Profit -$116.57 -$135.21 $34.7 -$10.57
Operating activities
Research & development $62.55 $815.91 $113.81 $43.24
Selling, general & administrative $107 $102.14 $54.29 $50.72
Total operating expenses $132.88 $277.06 $144.51 $88.93
Operating income -$249.46 -$412.26 -$109.81 -$99.5
Income from continuing operations
EBIT -$245.45 -$402.16 -$107.75 -$98.67
Income tax expense -$0.13 -$0.78 -$0.73 -$0.25
Interest expense $3.71 $10.34 $22.1 $1.46
Net income
Net income -$249.03 -$411.72 -$129.12 -$99.87
Income (for common shares) -$249.03 -$411.72 -$129.12 -$99.87
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$48.68 -$67.41 -$57.42 -$128.78
Operating activities
Depreciation $5.91 $5.64 $5.85 $0.39
Business acquisitions & disposals -$0.28
Stock-based compensation $1.7 $2.99 $1.58 $2.73
Total cash flows from operations -$60.58 -$64.12 -$99.59 -$49.09
Investing activities
Capital expenditures -$10.96 -$14.19 -$13.03 -$20.9
Investments
Total cash flows from investing -$13.42 -$14.21 -$13.16 -$20.94
Financing activities
Dividends paid
Sale and purchase of stock $0.23 $0.07 $235.97 $34.43
Net borrowings -$1.44 -$1.27 -$1.26 -$1.13
Total cash flows from financing -$1.21 -$1.2 $234.71 $33.3
Effect of exchange rate $1.43 $0.84
Change in cash and equivalents -$75.21 -$79.52 $121.96 -$36.73
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$249.03 -$411.72 -$129.12 -$99.87
Operating activities
Depreciation $23.74 $15.67 $10.67 $7.16
Business acquisitions & disposals -$0.28
Stock-based compensation $9.19 $14.96 $14.24 $19.56
Total cash flows from operations -$286.18 -$733.13 $522.4 -$86.96
Investing activities
Capital expenditures -$88.02 -$124.22 -$36.33 -$11.17
Investments -$1.16 $38.08
Total cash flows from investing -$93.5 -$127.9 -$45.27 $28.18
Financing activities
Dividends paid
Sale and purchase of stock $67.39 $373.15 $867.72
Net borrowings -$4.22 -$28.18 -$47.88 $67.98
Total cash flows from financing $63.17 $344.96 $819.83 $67.98
Effect of exchange rate $0.84 $4.94 -$5.05 $0.11
Change in cash and equivalents -$316.5 -$516.07 $1296.96 $9.2
Fundamentals
Market cap $678.49M
Enterprise value $256.46M
Shares outstanding 223.92M
Revenue $42.88M
EBITDA -$276.99M
EBIT -$294.78M
Net Income -$302.30M
Revenue Q/Q 47.01%
Revenue Y/Y -55.77%
P/E ratio -2.24
EV/Sales 5.98
EV/EBITDA -0.93
EV/EBIT -0.87
P/S ratio 15.82
P/B ratio 1.13
Book/Share 2.69
Cash/Share 2.07
EPS -$1.35
ROA -33.81%
ROE -48.41%
Debt/Equity 0.61
Net debt/EBITDA 0.81
Current ratio 3.56
Quick ratio 3.41